Gross Profit Comparison: Vertex Pharmaceuticals Incorporated and Ligand Pharmaceuticals Incorporated Trends

Vertex vs. Ligand: A Decade of Profit Trends

__timestampLigand Pharmaceuticals IncorporatedVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201455402000519428000
Thursday, January 1, 201566107000906794000
Friday, January 1, 20161034020001491717000
Sunday, January 1, 20171357360002213533000
Monday, January 1, 20182451160002638058000
Tuesday, January 1, 20191089350003615063000
Wednesday, January 1, 20201560000005469383000
Friday, January 1, 20212149570006670200000
Saturday, January 1, 20221434180007850400000
Sunday, January 1, 2023962650008607000000
Monday, January 1, 20249489600000
Loading chart...

Cracking the code

A Tale of Two Pharmaceuticals: Vertex vs. Ligand

In the ever-evolving landscape of pharmaceuticals, Vertex Pharmaceuticals Incorporated and Ligand Pharmaceuticals Incorporated have showcased intriguing trends in their gross profit margins over the past decade. From 2014 to 2023, Vertex Pharmaceuticals has demonstrated a remarkable growth trajectory, with its gross profit surging by over 1,500%, reaching a peak in 2023. This growth underscores Vertex's strategic advancements and market adaptability.

Conversely, Ligand Pharmaceuticals has experienced a more modest increase, with its gross profit peaking in 2018 before experiencing fluctuations. Despite these variations, Ligand's gross profit in 2023 remains approximately 74% higher than in 2014, highlighting its resilience in a competitive market.

These trends reflect broader industry dynamics, where innovation and strategic positioning play pivotal roles in financial performance. As the pharmaceutical sector continues to evolve, these companies' trajectories offer valuable insights into the industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025